Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipirinen is a proprietary composition consisting of phosphatidylserine (PS) conjugated to omega-3 fatty acids enriched with eicosapentaenoic acid (EPA). It is the active ingredient in medical foods such as Vayarin and Vay-R, which are orally administered for the clinical dietary management of complex lipid imbalances associated with attention deficit hyperactivity disorder (ADHD), particularly in children[1][2][4]. Lipirinen is designed to address specific lipid nutritional requirements that cannot be met by normal diet or standard dietary supplements. The mechanism of action involves providing essential long-chain polyunsaturated fatty acids important for brain and central nervous system development and function. Phosphatidylserine enriched with omega-3s has been shown to influence neuronal membrane integrity, signal transduction pathways (including regulation of sodium/calcium ATPase and protein kinase C), neurotransmitter activity (acetylcholine, dopamine, noradrenaline), and may increase brain glucose concentrations[2][3]. The exact mechanism by which Lipirinen exerts its effects in ADHD remains not fully understood.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lipirinen.